Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitors

MLA

Akifumi Hagiwara, et al. Diffusion MRI Is an Early Biomarker of Overall Survival Benefit in IDH Wild-Type Recurrent Glioblastoma Treated with Immune Checkpoint Inhibitors. June 2022. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....0c76e843c8f23f82a9accfa7560b644b&authtype=sso&custid=ns315887.

APA

Akifumi Hagiwara, Talia C Oughourlian, Nicholas S Cho, Jacob Schlossman, Chencai Wang, Jingwen Yao, Catalina Raymond, Richard Everson, Kunal Patel, Sergey Mareninov, Fausto J Rodriguez, Noriko Salamon, Whitney B Pope, Phioanh L Nghiemphu, Linda M Liau, Robert M Prins, Timothy F Cloughesy, & Benjamin M Ellingson. (2022). Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitors.

Chicago

Akifumi Hagiwara, Talia C Oughourlian, Nicholas S Cho, Jacob Schlossman, Chencai Wang, Jingwen Yao, Catalina Raymond, et al. 2022. “Diffusion MRI Is an Early Biomarker of Overall Survival Benefit in IDH Wild-Type Recurrent Glioblastoma Treated with Immune Checkpoint Inhibitors,” June. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....0c76e843c8f23f82a9accfa7560b644b&authtype=sso&custid=ns315887.